The growth of a small number of cells from each of two chemically induced BALB/c sarcomas was enhanced when x-irradiated (15,000 rads) cells of the same sarcoma were mixed with the tumor inoculum. This enhancement did not occur if the recipients had been given a total body x-irradiation of 450 rads. Tumor neutralization (Winn) tests showed that tumor cells irradiated in vitro enhanced tumor growth only in the presence of radiosensitive cells present in the spleens of both nonimmune and tumor-bearing mice. On the basis of these findings we postulate that tumor antigen blocks effective tumor immunity by a mechanism that involves a suppressor cell population.
Even though lymphocytes from tumor-bearing animals often can kill cells from the respective tumors in vitro, neoplasms that possess tumor-specific transplantation antigens (TSTA) are usually not rejected by their hosts in vivo. Rather, for tumors carrying TSTA to be rejected, the animals must be first immunized against the tumor and the cell dose used for subsequent challenge must not be greater than 1-3 orders of magnitude above the minimal dose needed for outgrowth in unimmunized controls (1) .
Several mechanisms which contribute to the escape of antigenic tumors from immunological control have been described (2) (3) (4) (5) (6) . Specific blocking factors (SBF), which inhibit ("block") the in vitro destruction of tumor cells by immune T lymphocytes, represent one of the more extensively studied immunologically specific escape mechanisms (7, 8) . Tumor antigens (7) (8) (9) , antibodies (7) , antigen-antibody complexes (3, 10) , and probably also host-cell derived immunosuppressive factors, different from antibodies (11) , can act as SBF. Suppressor cells that can turn off the immune response to tumor antigens in a specific or nonspecific way represent another escape mechanism that has attracted great attention lately (5, (12) (13) (14) (15) .
Tumor antigen can both enhance tumor growth (9, 16, 17) and abolish delayed hypersensitivity to itself in vivo (17) . To achieve this, the antigen can be inoculated in the form of a soluble extract or as intact tumor cells that have been rendered incapable of dividing by a heavy dose of x-irradiation (in this paper, referred to as HR cells). One interpretation of these findings is that the antigen inhibits the effector cells directly or prevents their activation. This interpretation is supported by the evidence that free antigen can inhibit the cytotoxic effect of sensititized T lymphocytes in vitro (8, 18, 19) . However, certain other findings indicate that antigen will impair antitumor immunity by interacting with a suppressor cell population rather than directly with the effector cells (12) . Furthermore, two sets of recent data suggest that this interaction results in the production of specific immunosuppressive substances.
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First, a Thy-l-positive lymphocyte population present in the spleens of tumor-bearing mice has been shown to synthesize SBF in vitro (20) . Thy-l-positive lymphocytes from nonimmune (control) mice could also make SBF in vitro, provided that a T-cell deprived spleen cell population from mice carrying the respective tumor (and itself unable to form SBF) was added (20) . This latter observation indicates that SBF can be produced by T lymphocytes from nonimmune donors; operationally, these lymphocytes can be referred to as "suppressor lymphocytes." Second, SBF isolated from the serum of mice with 3-methylcholanthrene-induced sarcomas as glycoproteins with a molecular weight of 56,000 were found to bind to both the respective tumor cells and to "unblocking" antibodies obtained from the serum of tumor-immunized mice; the same unblocking antibodies could not specifically bind to the respective tumor antigens (11) . These SBF were therefore not likely to be TSTA but instead were probably specific immunosuppressive factors similar to those seen in certain nontumor systems (21, 22) . This paper describes experiments performed on three transplanted lines of 3-methylcholanthrene-induced BALB/c sarcomas to study whether tumor antigen can enhance tumor growth in vivo by interacting with host (suppressor) cells different from the actual effector cells.
MATERIALS AND METHODS
Mice and Tumors. BALB/c mice were bred by brother/ sister mating in our laboratory and were regularly checked for their ability to accept intrastrain skin grafts; 8 The mixtures were incubated at room temperature for 30 min and then inoculated subcutaneously into each flank. Controls were always included to make certain that spleen cells from tumor-bearing mice did not contain cells that could grow out to palpable tumors (they never did).
RESULTS
Effect of Admixed HR Tumor Cells on Tumor Growth. Using tumors 1420 and 1425, we first studied whether the admixture of HR cells in the inoculum influenced the ability of a small dose (104) of cells from the same or a different tumor to grow in syngeneic mice. The recipient-mice were either untreated or had been preimmunized against the respective tumors. They were inoculated subcutaneously on the right side. Table 1 shows that added HR cells significantly enhanced the growth of the challenge cells in both untreated and preimmunized syngeneic hosts, as compared to groups in which only the tumor cells were inoculated. This enhancement was seen only when HR and tumor cells were inoculated together and not when the HR cells were given on the contralateral side.
1420 HR cells enhanced sarcoma 1420 and not 1425, and 1425 HR cells enhanced sarcoma 1425. Although 1425 HR cells also gave some enhancement of sarcoma 1420, this enhancement was not statistically significant. The same pattern of specificity was observed when the data were expressed as fractions of all inoculated tumor sites having tumor at 2, 3, and 4 weeks after challenge rather than as mean tumor diameters (data not shown).
Effect of X-Irradiation of Recipient Mice on Tumor EnImmunology: Helistr6m and Hellstr6m hancement by HR Cells. The enhancing effect of added HR had no effect on growth of the tumor cells (data not shown). cells was studied further by performing an experiment similar When spleen cells from mice bearing tumor 1425 (group 3) to that described in Table 1 but including groups in which the or from nonimmune (normal) mice (group 5) were added to the preimmunized mice were given 450 rads of total body x-irraimmune cells, tumor growth was greater than that seen with diation the day before challenge. As seen before in nonirradiimmune cells alone, although this difference was not statistically ated, preimmunized mice, HR cells enhanced tumor growth.
significant. However, if the tumor-bearer or normal spleen cells However, HR cells did not enhance tumor growth in immunwere given 450 rads (groups 4 and 6), this tendency of enhanced ized mice that had been preirradiated ( (Table 3) . We speculated that the reason why spleen cells from mice that had been preimmunized against 1425 were were not more effective in enhancing tumor growth than shown added to the mixtures inoculated.
in Table 3 may have been that the amount of antigen released As shown in Table 3 Table 3 . 1425 HR cells enhanced tumor growth but this enhancement occurred only when nonirradiated normal spleen cells were included in the cell mixtures inoculated (group 5). Furthermore, the addition of 1420 HR cells (a noncrossreacting tumor) to the inoculum of tumor cells, immune cells, and spleen cells had no effect on tumor growth.
Finally, a preliminary experiment was performed to test whether the spleen cells that act in concert with HR cells in enhancing tumor growth are sensitive, in the presence of complement, to treatment with a previously described anti-T cell serum (23) and complement. The data showed that the spleen cells were sensitive to this serum (in the presence of complement). Subsequent experiments using mouse antiThy/sera have given similar results (data not shown). DISCUSSION We demonstrate that cells from chemically induced BALB/c sarcomas 1420 and 1425 grew better when inoculated into mice together with heavily x-irradiated (HR) cells from the same sarcoma than when given alone; the HR cells were known to possess TSTA because they could induce transplantation resistance to the respective tumors. Tumor enhancement was seen both in mice preimmunized to cells of the respective sarcomas and in untreated animals.
The enhancement seen with tumor 1425 was highly specific; only a weak statistically nonsignificant enhancement was observed when cells from sarcoma 1420 were inoculated together with HR cells from tumor 1425. The latter finding may reflect some immunological crossreactivity between the two sarcomas (unpublished data). The fact that sublethal irradiation of the mice totally abolished the enhancing effect of the HR cells (Table 2) argues against its being simply due to a "feeder" effect of the added HR cells (24) . The HR cells enhanced tumor growth only when mixed with the test challenge, indicating that the dose of antigen inoculated (5 X 106 nondividing cells) was too small to achieve a systemic effect. Our findings agree with published reports that antigen can enhance tumor growth (8, 9, 16, 17) , and they may explain why the tumor transplantation resistance detected in preimmunized hosts is generally overcome when the mice are challenged with large inocula.
The remainder of our experiments concerned the question of whether the observed enhancing effect of HR cells was due to a direct inactivation of the effector cells or was more indirect (e.g., involving a suppressor cell mechanism).
Suppressor cells are generally sensitive to a sublethal dose of X-irradiation (25) , whereas the ability of preimmunized mice to reject antigenic tumor cells is known to be resistant to such radiation (1) . Experiments performed to test whether HR cells could enhance tumor growth in sublethally x-irradiated hosts preimmunized to the tumor showed that the enhancing effect of antigen was indeed abolished by radiation. That led us to test whether spleen cells from either nonimmune or tumor-bearing mice could facilitate tumor growth in sublethally irradiated mice when mixed with spleen cells from mice immune to the respective tumor. A radiosensitive population of spleen cells was found to partially abrogate the ability of an immune lymphocyte population to inhibit tumor growth. No difference was seen in this respect between spleen cells from nonimmune mice and from animals bearing the respective tumor; these data are at variance with those of Fujimoto et al. (26) , probably because of differences between the experimental systems studied.
We speculated that the effect seen with added tumor-bearer or normal spleen cells was only partial because the amount of tumor antigen present was insufficient to fully activate suppressor cells. We therefore determined whether both 1425 HR cells and nonimmune spleen cells were needed for substantially enhancing the growth of tumor 1425 in sublethally irradiated mice; spleen cells from mice immunized to 1425 were added as the source of tumor immunity. Significant enhancement was seen only when the 1425 tumor cells used for challenge were mixed with both 1425 HR cells and nonirradiated spleen cells. The spleen cells responsible for this effect were sensitive to treatment with an anti-T serum and complement, indicating that they were T lymphocytes. However, a much better characterization of the surface markers of the suppressor cells is needed.
We suggest the following model, which is similar to one proposed by Gershon et al. (12) , as an explanation of our findings. Tumor antigen in the form of HR cells, which will induce Immunology: Hellstr6m 
with antibodies in the form of antigen-antibody complexes. This enhancement operates via an indirect mechanism which involves a T lymphocyte population present in the spleen (and probably also elsewhere) and which is sensitive to sublethal doses of x-irradiation. This lymphocyte population performs a suppressor cell function. As indicated by published findings (7, 8, 18, 19) , tumor antigen may also inhibit the effector (or "prekiller") cells directly, but we postulate that such inhibition occurs primarily when the antigen is present in a dose sufficiently large to compete with tumor cells for the receptors on the immune lymphocytes. Furthermore, we postulate that lymphocytes represented in normal spleens are, in the presence of tumor antigen, easily recruited into performing the suppressor function; this would explain why nonimmune lymphocytes were as efficient as tumor-bearers' lymphocytes in enhancing tumor growth. Our data are similar to findings on the in vitro formation of SBF by mouse spleen cultures (20, 27) , as summarized in the introduction. They suggest that the suppressor cell effects observed in this study might be related to SBF production and/or action.
Further experiments should clarify whether this model provides a major mechanism whereby antigenic tumors can escape from immunological destruction and to what extent the operationally defined suppressor cells inhibit effector cell activity by producing soluble SBF, including the 56,000-dalton immunosuppressive molecule recently identified (11) and antigen-antibody complexes (10) . If, indeed, effector cell activity is primarily inhibited via a suppressor cell mechanism, rather than by tumor antigens directly, there may be a good possibility for therapeutic intervention. However, one must also consider alternative explanations of the findings observed, including, among others, the modification by spleen cells of antigens present on HR tumor cells into a form capable of inhibiting immune effector cells (from a form that is not) and the formation of some lymphokines by spleen cells exposed to tumor antigens "immunostimulatory" (28) to the tumor and thereby counterbalancing tumor inhibition by immune lymphocytes.
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